Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma

Sherven Sharma, Raj K. Batra, Seok Chul Yang, Sven Hillinger, L. I. Zhu, Kimberly Calica Atianzar, Robert M. Strieter, Karen Riedl, Min Huang, Steven M. Dubinett

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The antitumor efficiency of dendritic cells transduced with an adenovirus vector expressing interleukin (IL)-7 (DC-AdIL-7) was evaluated in a murine model of spontaneous bronchoalveolar cell carcinoma. These transgenic mice (CC-10 TAg), expressing the SV40 large T antigen under the Clara cell promoter, develop bilateral multifocal pulmonary adenocarcinomas and die at 4 months as a result of progressive pulmonary tumor burden. Injection of DC-AdIL-7 in the axillary lymph node region (ALNR) weekly for 3 weeks led to a marked reduction in tumor burden with extensive lymphocytic infiltration of the tumors and enhanced survival. The antitumor responses were accompanied by the enhanced elaboration of interferon (IFN)-γ and IL-12 as well as an increase in the antiangiogenic chemokines, IFN-γ-inducible protein 10 (IP-10/CXCL10) and monokine induced by IFN-γ (MIG/CXCL9). In contrast, production of the immunosuppressive mediators IL-10, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), and the proangiogenic modulator vascular endothelial growth factor (VEGF) decreased in response to DC-AdIL-7 treatment. Significant reduction in tumor burden in a model in which tumors develop in an organ-specific manner provides a strong rationale for further evaluation of DC-AdIL-7 in regulation of tumor immunity and its use in lung cancer genetic immunotherapy.

Original languageEnglish (US)
Pages (from-to)1511-1524
Number of pages14
JournalHuman Gene Therapy
Volume14
Issue number16
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Interleukin-7
Tumor Burden
Dendritic Cells
Carcinoma
Lung
Interferons
Chemokine CXCL10
Monokines
Genes
Polyomavirus Transforming Antigens
Neoplasms
Viral Tumor Antigens
Transforming Growth Factors
Interleukin-12
Immunosuppressive Agents
Chemokines
Dinoprostone
Adenoviridae
Interleukin-10
Immunotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. / Sharma, Sherven; Batra, Raj K.; Yang, Seok Chul; Hillinger, Sven; Zhu, L. I.; Atianzar, Kimberly Calica; Strieter, Robert M.; Riedl, Karen; Huang, Min; Dubinett, Steven M.

In: Human Gene Therapy, Vol. 14, No. 16, 01.11.2003, p. 1511-1524.

Research output: Contribution to journalArticle

Sharma, S, Batra, RK, Yang, SC, Hillinger, S, Zhu, LI, Atianzar, KC, Strieter, RM, Riedl, K, Huang, M & Dubinett, SM 2003, 'Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma', Human Gene Therapy, vol. 14, no. 16, pp. 1511-1524. https://doi.org/10.1089/104303403322495025
Sharma, Sherven ; Batra, Raj K. ; Yang, Seok Chul ; Hillinger, Sven ; Zhu, L. I. ; Atianzar, Kimberly Calica ; Strieter, Robert M. ; Riedl, Karen ; Huang, Min ; Dubinett, Steven M. / Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. In: Human Gene Therapy. 2003 ; Vol. 14, No. 16. pp. 1511-1524.
@article{f3d196fe0ace4f5a86a498dde11e2b64,
title = "Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma",
abstract = "The antitumor efficiency of dendritic cells transduced with an adenovirus vector expressing interleukin (IL)-7 (DC-AdIL-7) was evaluated in a murine model of spontaneous bronchoalveolar cell carcinoma. These transgenic mice (CC-10 TAg), expressing the SV40 large T antigen under the Clara cell promoter, develop bilateral multifocal pulmonary adenocarcinomas and die at 4 months as a result of progressive pulmonary tumor burden. Injection of DC-AdIL-7 in the axillary lymph node region (ALNR) weekly for 3 weeks led to a marked reduction in tumor burden with extensive lymphocytic infiltration of the tumors and enhanced survival. The antitumor responses were accompanied by the enhanced elaboration of interferon (IFN)-γ and IL-12 as well as an increase in the antiangiogenic chemokines, IFN-γ-inducible protein 10 (IP-10/CXCL10) and monokine induced by IFN-γ (MIG/CXCL9). In contrast, production of the immunosuppressive mediators IL-10, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), and the proangiogenic modulator vascular endothelial growth factor (VEGF) decreased in response to DC-AdIL-7 treatment. Significant reduction in tumor burden in a model in which tumors develop in an organ-specific manner provides a strong rationale for further evaluation of DC-AdIL-7 in regulation of tumor immunity and its use in lung cancer genetic immunotherapy.",
author = "Sherven Sharma and Batra, {Raj K.} and Yang, {Seok Chul} and Sven Hillinger and Zhu, {L. I.} and Atianzar, {Kimberly Calica} and Strieter, {Robert M.} and Karen Riedl and Min Huang and Dubinett, {Steven M.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1089/104303403322495025",
language = "English (US)",
volume = "14",
pages = "1511--1524",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "16",

}

TY - JOUR

T1 - Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma

AU - Sharma, Sherven

AU - Batra, Raj K.

AU - Yang, Seok Chul

AU - Hillinger, Sven

AU - Zhu, L. I.

AU - Atianzar, Kimberly Calica

AU - Strieter, Robert M.

AU - Riedl, Karen

AU - Huang, Min

AU - Dubinett, Steven M.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - The antitumor efficiency of dendritic cells transduced with an adenovirus vector expressing interleukin (IL)-7 (DC-AdIL-7) was evaluated in a murine model of spontaneous bronchoalveolar cell carcinoma. These transgenic mice (CC-10 TAg), expressing the SV40 large T antigen under the Clara cell promoter, develop bilateral multifocal pulmonary adenocarcinomas and die at 4 months as a result of progressive pulmonary tumor burden. Injection of DC-AdIL-7 in the axillary lymph node region (ALNR) weekly for 3 weeks led to a marked reduction in tumor burden with extensive lymphocytic infiltration of the tumors and enhanced survival. The antitumor responses were accompanied by the enhanced elaboration of interferon (IFN)-γ and IL-12 as well as an increase in the antiangiogenic chemokines, IFN-γ-inducible protein 10 (IP-10/CXCL10) and monokine induced by IFN-γ (MIG/CXCL9). In contrast, production of the immunosuppressive mediators IL-10, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), and the proangiogenic modulator vascular endothelial growth factor (VEGF) decreased in response to DC-AdIL-7 treatment. Significant reduction in tumor burden in a model in which tumors develop in an organ-specific manner provides a strong rationale for further evaluation of DC-AdIL-7 in regulation of tumor immunity and its use in lung cancer genetic immunotherapy.

AB - The antitumor efficiency of dendritic cells transduced with an adenovirus vector expressing interleukin (IL)-7 (DC-AdIL-7) was evaluated in a murine model of spontaneous bronchoalveolar cell carcinoma. These transgenic mice (CC-10 TAg), expressing the SV40 large T antigen under the Clara cell promoter, develop bilateral multifocal pulmonary adenocarcinomas and die at 4 months as a result of progressive pulmonary tumor burden. Injection of DC-AdIL-7 in the axillary lymph node region (ALNR) weekly for 3 weeks led to a marked reduction in tumor burden with extensive lymphocytic infiltration of the tumors and enhanced survival. The antitumor responses were accompanied by the enhanced elaboration of interferon (IFN)-γ and IL-12 as well as an increase in the antiangiogenic chemokines, IFN-γ-inducible protein 10 (IP-10/CXCL10) and monokine induced by IFN-γ (MIG/CXCL9). In contrast, production of the immunosuppressive mediators IL-10, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), and the proangiogenic modulator vascular endothelial growth factor (VEGF) decreased in response to DC-AdIL-7 treatment. Significant reduction in tumor burden in a model in which tumors develop in an organ-specific manner provides a strong rationale for further evaluation of DC-AdIL-7 in regulation of tumor immunity and its use in lung cancer genetic immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=10744230076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230076&partnerID=8YFLogxK

U2 - 10.1089/104303403322495025

DO - 10.1089/104303403322495025

M3 - Article

VL - 14

SP - 1511

EP - 1524

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 16

ER -